<DOC>
	<DOCNO>NCT00201799</DOCNO>
	<brief_summary>This study evaluate efficacy infliximab reduce incidence grade II-IV acute graft versus host disease day +100 post-transplant patient undergo allogeneic hematopoietic stem cell transplant .</brief_summary>
	<brief_title>Infliximab Prevention Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Rationale : Acute graft host disease ( GvHD ) remain barrier successful hematopoietic stem cell transplantation ( HCT ) use treatment cancer patient . GvHD result lack compatibility donor recipient . Research suggest another primary cause GvHD come cytokine , substance produce cell immune system affect immune response positive negative way . Infliximab antibody directly target cytokine associate GvHD . This study build upon previous research ass infliximab 's ability prevent GvHD HCT . Purpose : This study evaluate efficacy infliximab reduce incidence GvHD HCT . The safety approach , along change specific cytokine treatment , also measure . Treatment : Patients study receive infliximab intravenous infusion . Infliximab administer six dos , include one day chemotherapy radiotherapy , stem cell infusion , day 7 , 14 , 28 42 . Standard post-transplant treatment cyclosporine ( Neoral ) methotrexate ( Methotrexate ) also give intravenous infusion . Cyclosporine give day 1 , subsequent schedule determine individual basis . Methotrexate administer day 1 , 3 , 6 , 11 . Several test exams give throughout study closely monitor patient .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients undergo allogeneic HCT follow disorder : Acute myelogenous leukemia Acute lymphoblastic leukemia NonHodgkin 's lymphoma Hodgkin 's disease Multiple myeloma Chronic lymphocytic leukemia Chronic myeloid leukemia accelerate blast crisis time transplant . Age &gt; 20 yr Patients undergo allogeneic stem cell transplantation chronic myelogenous leukemia aplastic anemia exclude . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>